Unresolved issues in the management of endometrial cancer

References

• Kinkel K, Forstner R, Danza FM et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur. Radiol.19(7), 1565–1574 (2009).
   PubMed Web of Science ®Google Scholar
• Furukawa N, Takekuma M, Takahashi N, Hirashima Y. Intraoperative evaluation of myometrial invasion and histological type and grade in endometrial cancer: diagnostic value of frozen section. Arch. Gynecol. Obstet.281(5), 913–917 (2010).
   PubMedGoogle Scholar
• Frumovitz M, Slomovitz BM, Singh DK et al. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J. Am. Coll. Surg.199(3), 388–393 (2004).
   PubMed Web of Science ®Google Scholar
• Signorelli M, Guerra L, Buda A et al. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases. Gynecol. Oncol.115(2), 231–235 (2009).
   PubMed Web of Science ®Google Scholar
• Picchio M, Mangili G, Samanes Gajate AM et al. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging. Nucl. Med. Commun.31(6), 506–512 (2010).
   PubMedGoogle Scholar
• Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS. Can primary endometrial carcinoma stage-I be cured without surgery and radiation therapy. Gynecol. Oncol.20(2), 139–155 (1985).
   PubMed Web of Science ®Google Scholar
• Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG117(7), 879–883 (2010).
   PubMedGoogle Scholar
• Farthing A. Conserving fertility in the management of gynaecological cancers. BJOG113(2), 129–134 (2006).
   PubMedGoogle Scholar
• Ushijima K, Yahata H, Yoshikawa H et al. Multicenter Phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J. Clin. Oncol.25(19), 2798–2803 (2007).
   PubMed Web of Science ®Google Scholar
• Hahn HS, Yoon SG, Hong JS et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int. J. Gynecol. Cancer19(6), 1068–1073 (2009).
   PubMed Web of Science ®Google Scholar
• Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG116(1), 114–118 (2009).
   PubMedGoogle Scholar
• Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol. Endocrinol.25(10), 683–691 (2009).
   PubMed Web of Science ®Google Scholar
• Kinkel K, Kaji Y, Yu KK et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology212(3), 711–718 (1999).
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Arabi H, Thirabanjasak D, Quddus MR, Lawrence WD, Fehmi RA. Endometrial cancer diagnosed in young patients is not always a low-risk cancer. Mod. Pathol.21, 900 (2008).
   Google Scholar
• Suh DS, Kim JK, Kim KR et al. Reliability of magnetic resonance imaging in assessing myometrial invasion absence in endometrial carcinoma. Acta Obstet. Gynecol. Scand.88(9), 990–993 (2009).
   PubMed Web of Science ®Google Scholar
• Kothari R, Seamon L, Cohn D, Fowler J, O’Malley DM. Stage IV endometrial cancer after failed conservative management: a case report. Gynecol. Oncol.111(3), 579–582 (2008).
   PubMedGoogle Scholar
• Corrado G, Baiocco E, Carosi M, Vizza E. Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil. Steril.90(5), 2006.e2005–2008 (2008).
   PubMedGoogle Scholar
• Zivanovic O, Carter J, Kauff ND, Barakat RR. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol. Oncol.115(3), 504–509 (2009).
   PubMedGoogle Scholar
• Lin F, Zhang QJ, Zheng FY et al. Laparoscopically assisted versus open surgery for endometrial cancer – a meta-analysis of randomized controlled trials. Int. J. Gynecol. Cancer18(6), 1315–1325 (2008).
   PubMedGoogle Scholar
• Palomba S, Falbo A, Mocciaro R, Russo T, Zullo F. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol. Oncol.112(2), 415–421 (2009).
   PubMed Web of Science ®Google Scholar
• Walker JL, Piedmonte MR, Spirtos NM et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J. Clin. Oncol.27(32), 5331–5336 (2009).
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J. Clin. Oncol.27(32), 5337–5342 (2009).
   PubMed Web of Science ®Google Scholar
• Sanjuan A, Hernandez S, Pahisa J et al. Port-site metastasis after laparoscopic surgery for endometrial carcinoma: two case reports. Gynecol. Oncol.96(2), 539–542 (2005).
   PubMedGoogle Scholar
• Chen CCG, Straughn JM, Kilgore LC. Early abdominal incision recurrence in a patient with stage I adenocarcinoma of the endometrium. Obstet. Gynecol.104(5), 1170–1172 (2004).
   PubMedGoogle Scholar
• Walker J, Piedmonte M, Spirtos N et al. Recurrence and survival after randomization to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer (Gynecologic Oncology Group LAP2). Gynecol. Oncol.117(2), 393–393 (2010).
   Google Scholar
• Boggess JF, Gehrig PA, Cantrell L et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am. J. Obstet. Gynecol.199(4), 360.e1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Seamon LG, Cohn DE, Henretta MS et al. Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? Gynecol. Oncol.113(1), 36–41 (2009).
   PubMed Web of Science ®Google Scholar
• Soliman PT, Frumovitz M, Spannuth W et al. Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol. Oncol.119(2), 291–294 (2010).
   PubMedGoogle Scholar
• Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathological spread patterns of endometrial cancer – a Gynecologic Oncology Group study. Cancer60(8), 2035–2041 (1987).
   PubMed Web of Science ®Google Scholar
• Chi DS, Barakat RR, Palayekar MJ et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int. J. Gynecol. Cancer18(2), 269–273 (2008).
   PubMed Web of Science ®Google Scholar
• Nunns D, Williamson K, Swaney L, Davy M. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma. Int J. Gynecol. Cancer10(3), 233–238 (2000).
   PubMedGoogle Scholar
• Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health8, 8 (2008).
   PubMedGoogle Scholar
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet.105(2), 103–104 (2009).
   PubMed Web of Science ®Google Scholar
• Kitchener H, Swart AMC, Qian W, Amos C, Parmar MKB; ASTEC Study Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet373(9658), 125–136 (2009).
   PubMed Web of Science ®Google Scholar
• Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl Cancer Inst.100(23), 1707–1716 (2008).
   PubMedGoogle Scholar
• Fotopoulou C, Savvatis K, Kraetschell R, Schefold JC, Lichtenegger W, Sehouli J. Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status. Eur. J. Obstet. Gynecol. Reprod. Biol.149(2), 199–203 (2010).
   PubMedGoogle Scholar
• Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann. Surg. Oncol.17(3), 861–868 (2010).
   PubMedGoogle Scholar
• Hoekstra AV, Kim RJ, Small W et al. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol. Oncol.114(2), 273–278 (2009).
   PubMedGoogle Scholar
• Nomura H, Aoki D, Suzuki N et al. Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer. Int. J. Gynecol. Cancer16(2), 799–804 (2006).
   PubMed Web of Science ®Google Scholar
• Chan JK, Wu HS, Cheung MK, Shin JY, Osann K, Kapp DS. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol. Oncol.106(2), 282–288 (2007).
   PubMedGoogle Scholar
• Chan JK, Cheung MK, Huh WK et al. Therapeutic role of lymph node resection in endometrioid corpus cancer – a study of 12,333 patients. Cancer107(8), 1823–1830 (2006).
   PubMed Web of Science ®Google Scholar
• Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet375(9721), 1165–1172 (2010).
   PubMed Web of Science ®Google Scholar
• Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol. Oncol.62(2), 169–173 (1996).
   PubMed Web of Science ®Google Scholar
• Maccauro M, Lucignani G, Aliberti G et al. Sentinel lymph node detection following the hysteroscopic peritumoural injection of Tc-99m-labelled albumin nanocolloid in endometrial cancer. Eur. J. Nucl. Med. Mol. Imaging32(5), 569–574 (2005).
   PubMed Web of Science ®Google Scholar
• Keys HM, Roberts JA, Brunetto VL et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.92(3), 744–751 (2004).
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WLJ, Koper PCM et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet355(9213), 1404–1411 (2000).
   PubMed Web of Science ®Google Scholar
• Soderini A AJ, Sardi JE. Role of adjuvant radiotherapy (RT) in intermediate risk (1b G2–3–1c) endometrioid carcinoma (EC) after extended staging surgery (ESS). Preliminary reports of a randomised trial. Int. J. Gynecol. Cancer13(Suppl. 1), 1–22 (2003) (Abstract PO147).
   Google Scholar
• Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage-I endometrial carcinoma – clinical and histopathologic study of 540 patients. Obstet. Gynecol.56(4), 419–426 (1980).
   PubMed Web of Science ®Google Scholar
• Kong A, Simera I, Collingwood M, Williams C, Kitchener H; Cochrane Gynaecological Cancer Group. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann. Oncol.18, 1595–1604 (2007).
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WLJ, Koper PC et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol. Oncol.89(2), 201–209 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG114(11), 1313–1320 (2007).
   PubMed Web of Science ®Google Scholar
• Blake P, Swart AM, Orton J et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet373(9658), 137–146 (2009).
   PubMed Web of Science ®Google Scholar
• Nout RA, Smit V, Putter H et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet375(9717), 816–823 (2010).
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H et al. Randomized Phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.24(1), 36–44 (2006).
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Gibbons SK et al. A randomized Phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol. Oncol.112(3), 543–552 (2009).
   PubMed Web of Science ®Google Scholar
• Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br. J. Cancer95(3), 266–271 (2006).
   PubMed Web of Science ®Google Scholar
• Susumu N, Sagae S, Udagawa Y et al. Randomized Phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol. Oncol.108(1), 226–233 (2008).
   PubMed Web of Science ®Google Scholar
• Hogberg T, Rosenberg P, Kristensen G et al. A randomized Phase-III study on adjuvant treatment with radiation (RT) +/- chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J. Clin. Oncol.25(18S), (2007) (Abstract 5503).
   Google Scholar
• Hogberg T. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin. Oncol.20(6), 463–469 (2008).
   Web of Science ®Google Scholar
• Fader AN, Drake RD, O’Malley DM et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer115(10), 2119–2127 (2009).
   PubMed Web of Science ®Google Scholar
• Aapro MS, van Wijk FH, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann. Oncol.14(3), 441–448 (2003).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.22(19), 3902–3908 (2004).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brurietto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.22(11), 2159–2166 (2004).
   PubMed Web of Science ®Google Scholar
• Clamp AR, Maenpaa J, Cruickshank D et al. SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer. Br. J. Cancer94(1), 55–61 (2006).
   PubMed Web of Science ®Google Scholar
• Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel – long-term follow-up. Int. J. Gynecol. Cancer18(4), 803–808 (2008).
   PubMed Web of Science ®Google Scholar
• Humber CE, Tierney JF, Symonds RP et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann. Oncol.18(3), 409–420 (2007).
   PubMed Web of Science ®Google Scholar
• Dietrich CS, Modesitt SC, DePriest PD et al. The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.99(3), 557–563 (2005).
   PubMedGoogle Scholar
• Kelly MG, O’Malley DM, Hui P et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol.98(3), 353–359 (2005).
   PubMed Web of Science ®Google Scholar
• Low JSH, Wong EH, Tan HSK et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol. Oncol.97(1), 171–177 (2005).
   PubMed Web of Science ®Google Scholar
• Fader AN, Drake RD, O’Malley DM et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer115(10), 2119–2127 (2009).
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Creasman WT, Petterson F, Benedet JL, Shepherd JH. FIGO annual report on the results of treatment in gynecologic cancer. J. Epidemiol. Biostat.3, 35–62 (1998).
   Google Scholar
• Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol. Oncol.67(1), 56–60 (1997).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol. Oncol.107(2), 190–193 (2007).
   PubMed Web of Science ®Google Scholar
• Vandenput I, Van Calster B, Capoen A et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br. J. Cancer101(2), 244–249 (2009).
   PubMed Web of Science ®Google Scholar
• Landrum LM, Moore KN, Myers TKN et al. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case–control analysis. Gynecol. Oncol.112(2), 337–341 (2009).
   PubMed Web of Science ®Google Scholar
• Awtrey CS, Cadungog MG, Leitao MM et al. Surgical resection of recurrent endometrial carcinoma. Gynecol. Oncol.102(3), 480–488 (2006).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol. Oncol.103(1), 281–287 (2006).
   PubMed Web of Science ®Google Scholar
• Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol. Oncol.118(1), 14–18 (2010).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol. Oncol.78(2), 85–91 (2000).
   PubMed Web of Science ®Google Scholar
• Franco-Camps S, Cabrera S, Perez-Benavente A et al. Extraperitoneal laparoscopic approach for diagnosis and treatment of aortic lymph node recurrence in gynecologic malignancy. J. Minim. Invas. Gynecol.17(5), 570–575 (2010).
   PubMedGoogle Scholar
• Whitney CW, Brunetto VL, Zaino RJ et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.92(1), 4–9 (2004).
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.92(1), 10–14 (2004).
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A Phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.78(2), 212–216 (2000).
   PubMed Web of Science ®Google Scholar
• Ma BBY, Oza A, Eisenhauer E et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group. Int. J. Gynecol. Cancer14(4), 650–658 (2004).
   PubMed Web of Science ®Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control16(1), 8–13 (2009).
   PubMed Web of Science ®Google Scholar
• Grushko TA, Filiaci V, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.108(1), 3–9 (2008).
   PubMed Web of Science ®Google Scholar
• Konecny GE, Santos L, Winterhoff B et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer100(1), 89–95 (2009).
   PubMed Web of Science ®Google Scholar
• Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer16(5), 1897–1902 (2006).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Sill MW, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.116(1), 15–20 (2003).
   Google Scholar
• Konecny GE, Venkatesan N, Yang G et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer98(6), 1076–1084 (2008).
   PubMed Web of Science ®Google Scholar
• Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol. Oncol.113(3), 370–373 (2009).
   PubMed Web of Science ®Google Scholar
• Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol. Oncol.116(2), 286–289 (2010).
   PubMed Web of Science ®Google Scholar
• Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl Cancer Inst.92(11), 924–931 (2000).
   PubMed Web of Science ®Google Scholar
• Kang SY, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA102(3), 802–807 (2005).
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang SY, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl Acad. Sci. USA103(5), 1475–1479 (2006).
   PubMed Web of Science ®Google Scholar
• Samuels Y, Diaz LA, Schmidt-Kittler O et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell7(6), 561–573 (2005).
   PubMed Web of Science ®Google Scholar
• Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res.65(23), 10669–10673 (2005).
   PubMed Web of Science ®Google Scholar
• Hayes MP, Wang H, Espinal-Witter R et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res.12(20), 5932–5935 (2006).
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Biagi J et al. Molecular correlates associated with a Phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer – NCICIND 160. J. Clin. Oncol.24(18), 121S–121S (2006).
   Google Scholar
• Slomovitz BM, Burke T, Lu KH et al. Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: translational evaluation from a Phase II study. Gynecol. Oncol.104(3), S30–S31 (2007).
   Google Scholar
• Aghajanian C, Sill MW, Darcy K et al. A Phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol.27(Suppl. 15), (2009) (Abstract 5531).
   Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ et al. A Phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol.117(1), 37–40 (2010).
   PubMed Web of Science ®Google Scholar
• Correa R, Mackay H, Hirte HW et al. A Phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. J. Clin. Oncol.28(Suppl. 15), (2010) (Abstract 5038).
   Google Scholar